Lilly Reports Taltz-Zepbound Combo Beats Taltz Alone in Psoriasis Study
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are still awaited.
Topic
Eli Lilly
Topic
Eli Lilly
FDA Approves 8-Week Maintenance Dosing for EBGLYSS in Atopic Dermatitis
Eli Lilly's EBGLYSS label update from the FDA allows one subcutaneous maintenance dose every eight weeks for adults with moderate…
Eli Lilly Reports Positive Phase 3b Results for Ebglyss
Eli Lilly has reported positive phase 3b results for Ebglyss, with the topline disclosure signaling another late-stage win for th…
Lilly Signals Entry Into Aesthetics Market
Eli Lilly is looking to add aesthetics products for body, skin and hair, Endpoints News reports, positioning the drugmaker to com…
Lebrikizumab Shows Rapid Gains in Hand and Foot Atopic Dermatitis
Lilly reports Phase 3b data showing EBGLYSS (lebrikizumab-lbkz) achieved significant, rapid improvements in skin clearance, itch,…
EBGLYSS Hits Endpoints in Phase 3b Hand-and-Foot Atopic Dermatitis Trial
Lilly's Phase 3b ADtouch trial shows 53% of hand-and-foot atopic dermatitis patients on EBGLYSS reached clear or almost clear ski…
Lilly's Ebglyss Meets Endpoints in Phase 3b Hand and Foot AD Trial
Ebglyss met primary and secondary endpoints at 16 weeks in Phase 3b ADtouch, improving clearance, itch and pain in moderate-to-se…
Lebrikizumab Shows Rapid Gains in Hand and Foot Atopic Dermatitis
Lilly's Phase 3b data show EBGLYSS (lebrikizumab-lbkz) rapidly improved skin clearance, itch, pain, and patient satisfaction in m…
Lilly Psoriasis Trial Backs Immunometabolic Treatment Strategy
Lilly's psoriasis trial validates pairing skin-clearance endpoints with cardiometabolic measures, reframing psoriasis as a system…